Literature DB >> 9109465

Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.

H G Schrott1, V Bittner, E Vittinghoff, D M Herrington, S Hulley.   

Abstract

OBJECTIVES: To determine the proportion of volunteer women with established heart disease who have low-density lipoprotein cholesterol (LDL-C) levels at or below the National Cholesterol Education Program Adult Treatment Panel goals and to determine what factors are associated with levels above goal or not receiving lipid-lowering medication when indicated.
DESIGN: Cross-sectional measurement of lipids and lipoproteins, blood pressure, height, weight, and other demographic and cardiovascular risk factors in 2763 postmenopausal women with heart disease.
SETTING: At 18 centers throughout the United States, participants were recruited by means of lists of women with coronary heart disease from coronary units and catheterization laboratories, direct mail to age-eligible women, and advertisements. PATIENTS: Mean age of the cohort was 66.7 years (range, 44-79 years) and the distribution by race/ethnicity was 88.7% white, 7.9% African American, 2.0% Hispanic/Latina, 0.8% Asian/Pacific Islander, and 0.7% other. INTERVENTION: We report cross-sectional analysis of the cohort at baseline. OUTCOME MEASURES: We measured the frequency of achieving 1988 and 1993 Adult Treatment Panel treatment goals, and of being on a regimen of lipid-lowering medication.
RESULTS: Although 47% of participants were taking a lipid-lowering medication, 63% did not meet the 1988 treatment goal of LDL-C level less than 3.4 mmol/L (130 mg/dL) and 91% did not meet the 1993 goal of LDL-C level less than 2.6 mmol/L (100 mg/dL). Factors independently associated with achieving the earlier goal were use of lipid-lowering medication, marital status, education, body mass index, exercise, hypertension, diabetes, gallbladder disease, and first diagnosis of coronary heart disease after 1990. Failure to use lipid-lowering medication was associated with age, being African American, marital status, body mass index, lack of exercise, alcohol consumption, current smoking, and first diagnosis of coronary heart disease before 1985.
CONCLUSION: The majority of women enrolled in the trial had LDL-C levels that significantly exceeded the treatment goals set by the 1988 and 1993 Adult Treatment Panel guidelines. Better implementation of these guidelines among women with coronary disease would be highly desirable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109465

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  24 in total

1.  Statins: underused by those who would benefit.

Authors:  S B Hulley; D Grady; W S Browner
Journal:  BMJ       Date:  2000-10-21

Review 2.  Hormone replacement therapy for prevention of coronary heart disease: current evidence.

Authors:  P S Khurana; C Khurana; J Hsia
Journal:  Curr Atheroscler Rep       Date:  2001-09       Impact factor: 5.113

3.  Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.

Authors:  S R Majumdar; J H Gurwitz; S B Soumerai
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

Review 4.  University of California Commission on the Future of Medical Education. July 1997. Final report.

Authors: 
Journal:  West J Med       Date:  1998-05

5.  Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction.

Authors:  John Z Ayanian; Bruce E Landon; Mary Beth Landrum; James R Grana; Barbara J McNeil
Journal:  J Gen Intern Med       Date:  2002-02       Impact factor: 5.128

Review 6.  Statin therapy after acute myocardial infarction: are we adequately treating high-risk patients?

Authors:  Gregg C Fonarow
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

7.  Undertreatment of hypercholesterolaemia: a population-based study.

Authors:  A K Mantel-Teeuwisse; W M M Verschuren; O H Klungel; D Kromhout; A D Lindemans; J Avorn; A J Porsius; A de Boer
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

Review 8.  Therapy to reduce risk of coronary heart disease.

Authors:  Daniel J Rader
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

9.  General practitioners' adherence with clinical reminders for secondary prevention of dyslipidemia.

Authors:  Geva Vashitz; Joachim Meyer; Harel Gilutz
Journal:  AMIA Annu Symp Proc       Date:  2007-10-11

10.  Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?

Authors:  Steven A Grover; Louis Coupal; Mohammed Kaouache; Ilka Lowensteyn
Journal:  Can J Cardiol       Date:  2007-05-01       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.